SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on October 24, 2002; DOI 10.1182/blood-2002-05-1339. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-05-1339v1 101/5/1962    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Granziero, L. Articles by Caligaris-Cappio, F. Search for Related Content PubMed PubMed Citation Articles by Granziero, L. Articles by Caligaris-Cappio, F. Related Collections Immunobiology Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 March 2003, Vol. 101, No. 5, pp. 1962-1969 NEOPLASIA CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes Luisa Granziero, Paola Circosta, Cristina Scielzo, Elisa Frisaldi, Stefania Stella, Massimo Geuna, Silvia Giordano, Paolo Ghia, and Federico Caligaris-Cappio From the Department of Oncological Sciences, University of Torino, Institute for Cancer Research and Treatment (IRCC), Candiolo (TO) and Division of Clinical Immunology and Hematology, Ospedale Mauriziano Umberto I, Torino, Italy. Growth and survival of chronic B-cell tumors are favored by the malignant cell's capacity to respond to selected microenvironmental stimuli provided by nontumoral bystander cells. To investigate which mechanisms operate in these crosstalks and whether they are malignancy-related or reproduce the mechanisms used by normal B cells we have studied the expression and functional role of semaphorin CD100 (now called Sema4D) in chronic lymphocytic leukemia (CLL) cells and normal CD5+ B cells. We demonstrate here that (1) leukemic and normal CD5+ B lymphocytes uniformly express CD100; (2) the CD100 high-affinity receptor Plexin-B1 is expressed by bone marrow stromal cells, follicular dendritic cells, and activated T lymphocytes, and is thus available to CD100+ lymphocytes in different specific microenvironments; and (3) upon interaction between CD100 and Plexin-B1 both CLL and normal CD5+ B cells increase their proliferative activity and extend their life span. These findings establish that Plexin-B1 is an easily accessible receptor for CD100 within the immune system. The encounter of CD100+ leukemic cells with Plexin-B1 may promote the proliferation and survival of malignant cells. The crosstalk operated by the CD100/Plexin-B1 interaction is not malignancy related but reproduces a mechanism used by normal CD5+ B cells. © 2003 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: L. Capparuccia and L. Tamagnone Semaphorin signaling in cancer cells and in cells of the tumor microenvironment - two sides of a coin J. Cell Sci., June 1, 2009; 122(11): 1723 - 1736. [Abstract] [Full Text] [PDF] J. BOELENS, S. LUST, B. VANHOECKE, and F. OFFNER Chronic Lymphocytic Leukaemia Anticancer Res, February 1, 2009; 29(2): 605 - 615. [Abstract] [Full Text] [PDF] J. R. Sierra, S. Corso, L. Caione, V. Cepero, P. Conrotto, A. Cignetti, W. Piacibello, A. Kumanogoh, H. Kikutani, P. M. Comoglio, et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages J. Exp. Med., July 7, 2008; 205(7): 1673 - 1685. [Abstract] [Full Text] [PDF] P. E. M. Patten, A. G. S. Buggins, J. Richards, A. Wotherspoon, J. Salisbury, G. J. Mufti, T. J. Hamblin, and S. Devereux CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment Blood, May 15, 2008; 111(10): 5173 - 5181. [Abstract] [Full Text] [PDF] J. Durig, P. Ebeling, F. Grabellus, U. R. Sorg, M. Mollmann, P. Schutt, J. Gothert, L. Sellmann, S. Seeber, M. Flasshove, et al. A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease Cancer Res., September 15, 2007; 67(18): 8653 - 8661. [Abstract] [Full Text] [PDF] N. Takegahara, A. Kumanogoh, and H. Kikutani Semaphorins: a new class of immunoregulatory molecules Phil Trans R Soc B, September 29, 2005; 360(1461): 1673 - 1680. [Abstract] [Full Text] [PDF] S. Deaglio, T. Vaisitti, L. Bergui, L. Bonello, A. L. Horenstein, L. Tamagnone, L. Boumsell, and F. Malavasi CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival Blood, April 15, 2005; 105(8): 3042 - 3050. [Abstract] [Full Text] [PDF] I. Chabbert-de Ponnat, A. Marie-Cardine, R. J. Pasterkamp, V. Schiavon, L. Tamagnone, N. Thomasset, A. Bensussan, and L. Boumsell Soluble CD100 functions on human monocytes and immature dendritic cells require plexin C1 and plexin B1, respectively Int. Immunol., April 1, 2005; 17(4): 439 - 447. [Abstract] [Full Text] [PDF] F. K. Stevenson and F. Caligaris-Cappio Chronic lymphocytic leukemia: revelations from the B-cell receptor Blood, June 15, 2004; 103(12): 4389 - 4395. [Abstract] [Full Text] [PDF] A. Kumanogoh and H. Kikutani Immune semaphorins: a new area of semaphorin research J. Cell Sci., September 1, 2003; 116(17): 3463 - 3470. [Abstract] [Full Text] [PDF] I. Ishida, A. Kumanogoh, K. Suzuki, S. Akahani, K. Noda, and H. Kikutani Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses Int. Immunol., August 1, 2003; 15(8): 1027 - 1034. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020